OKYO Pharma Limited - American Depositary Shares — Financial Statements (NASDAQ:OKYO) | MetaTrader

Open full chart

News

What Makes OKYO Pharma (OKYO) a New Buy Stock

Piper Sandler initiates OKYO Pharma stock with Overweight rating

OKYO Pharma stock tumbles on $20 million public offering announcement

OKYO Pharma announces $20 million public offering of ordinary shares

OKYO Pharma transitions ATM equity offering to Leerink Partners as sales agent

OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program

OKYO Pharma to present urcosimod NCP study results at ASCRS meeting

H.C. Wainwright reiterates Buy rating on OKYO Pharma stock with $7 price target

OKYO Pharma stock rises after FDA confirms Phase 2b/3 trial design

OKYO Pharma reports successful FDA meeting on urcosimod clinical trial

OKYO Pharma receives FDA alignment on Phase 2b/3 trial for NCP treatment

OKYO Pharma stock gets FDA compassionate use approval for urcosimod